SANDRA STICKLER, BARBARA RATH, GERHARD HAMILTON^*

Oncology Research, Vol.32, No.5, pp. 799-805, 2024, DOI:10.32604/or.2024.045356

Abstract Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all pancreatic ductal adenocarcinomas (PDACs) and constitutes an attractive target for therapy. However, the most common KRAS mutations in PDAC are G12D (44%), G12V (34%) and G12R (20%) that are not amenable to treatment by KRAS G12C-directed cysteine-reactive KRAS inhibitors such as Sotorasib and Adagrasib that exhibit clinical efficacy in lung cancer. KRAS G12C mutant pancreatic cancer has been treated with Sotorasib but this mutation is detected only in 2%–3% of… More >

XINFENG ZHANG^1,2,#, SHUANG LI^2,#, MEIRU SONG^1,2, YUE CHEN³, LIANGZHENG CHANG³, ZHERUI LIU⁴, HONGYUAN DAI³, YUTAO WANG⁴, GANGQI YANG³, YUN JIANG^5,6,*, YINYING LU^1,2,*

Oncology Research, Vol.32, No.4, pp. 679-690, 2024, DOI:10.32604/or.2024.046231

Abstract Liver cancer is a prevalent malignant cancer, ranking third in terms of mortality rate. Metastasis and recurrence primarily contribute to the high mortality rate of liver cancer. Hepatocellular carcinoma (HCC) has low expression of focal adhesion kinase (FAK), which increases the risk of metastasis and recurrence. Nevertheless, the efficacy of FAK phosphorylation inhibitors is currently limited. Thus, investigating the mechanisms by which FAK affects HCC metastasis to develop targeted therapies for FAK may present a novel strategy to inhibit HCC metastasis. This study examined the correlation between FAK expression and the prognosis of HCC. Additionally, we explored the impact of… More >